Heresbach Denis, Manfredi Sylvain, D'halluin Pierre N, Bretagne Jean-François, Branger Bernard
Department of Gastroenterology, Service des Maladies de l'Appareil Digestif, CHU Pontchaillou, 35033 Rennes, France.
Eur J Gastroenterol Hepatol. 2006 Apr;18(4):427-33. doi: 10.1097/00042737-200604000-00018.
Several randomized studies have shown that colorectal cancer (CRC) screening by faecal occult blood test (FOBT) reduces CRC mortality. These trials have different designs, especially concerning FOBT frequency and duration, as well as the length of follow-up after stopping FOBT campaigns.
To review the effectiveness of screening for CRC with FOBT, to consider the reduction in mortality during or after screening or to identify factors associated with a significant mortality reduction.
A systematic review of trials of FOBT screening with a meta-analysis of four controlled trials selected for their biennial and population-based design. The main outcome measurements were mortality relative risk (RR) and 95% confidence interval (CI) of biennial FOBT during short (10 years, i.e. five or six rounds) or long-term (six or more rounds) screening periods, as well as after stopping screening and follow-up during 5-7 years. The meta-analysis used the Mantel-Haenszel method with fixed effects when the heterogeneity test was not significant, and used 'intent to screen' results.
Although the quality of the four trials was high, only three were randomized, and one used rehydrated biennial FOBT associated with a high colonoscopy rate (28%). A meta-analysis of mortality results showed that subjects allocated to screening had a reduction of CRC mortality during a 10-year period (RR 0.86; CI 0.79-0.94) although CRC mortality was not decreased during the 5-7 years after the 10-year (six rounds) screening period, nor in the last phase (8-16 years after the onset of screening) of a long-term (16 years or nine rounds) biennial screening. Whatever the design of the period of ongoing FOBT, CRC incidence neither decreased nor increased, although it was reduced for 5-7 years after the 10-year screening period. Neither the design nor the clinical or demographic parameters of these trials were independently associated with CRC mortality reduction.
Biennial FOBT decreased CRC mortality by 14% when performed over 10 years, without evidence-based benefit on CRC mortality when performed over a longer period. No independent predictors of CRC mortality reduction have been identified in order to allow a CRC screening programme in any subgroups of subjects at risk.
多项随机研究表明,通过粪便潜血试验(FOBT)进行结直肠癌(CRC)筛查可降低CRC死亡率。这些试验设计各异,尤其是在FOBT频率和持续时间,以及停止FOBT筛查活动后的随访时长方面。
回顾使用FOBT进行CRC筛查的有效性,考量筛查期间或之后的死亡率降低情况,或确定与显著降低死亡率相关的因素。
对FOBT筛查试验进行系统评价,并对四项因其两年一次且基于人群的设计而入选的对照试验进行荟萃分析。主要结局指标为两年一次FOBT在短期(10年,即五或六轮)或长期(六轮或更多轮)筛查期间的死亡率相对风险(RR)及95%置信区间(CI),以及停止筛查后5至7年随访期间的RR及CI。当异质性检验不显著时,荟萃分析采用固定效应的Mantel-Haenszel方法,并使用“意向筛查”结果。
尽管四项试验质量较高,但只有三项为随机试验,一项使用与高结肠镜检查率(28%)相关的复水两年一次FOBT。死亡率结果的荟萃分析显示,分配至筛查组的受试者在10年期间CRC死亡率降低(RR 0.86;CI 0.79 - 0.94),但在10年(六轮)筛查期后的5至7年期间CRC死亡率未降低,在长期(16年或九轮)两年一次筛查的最后阶段(筛查开始后8至16年)也未降低。无论正在进行的FOBT筛查期设计如何,CRC发病率既未下降也未上升,不过在10年筛查期后的5至7年有所降低。这些试验的设计、临床或人口统计学参数均未独立与CRC死亡率降低相关。
两年一次的FOBT在10年期间进行时可使CRC死亡率降低14%,但在更长时间进行时,未发现对CRC死亡率有基于证据的益处。尚未确定CRC死亡率降低的独立预测因素,以便在任何有风险的受试者亚组中开展CRC筛查项目。